Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised phase III trial of paclitaxel plus carboplatin (TC) therapy versus irinotecan plus cisplatin (CPT-P) therapy as a first line chemotherapy for clear cell carcinoma of the ovary

Trial Profile

Randomised phase III trial of paclitaxel plus carboplatin (TC) therapy versus irinotecan plus cisplatin (CPT-P) therapy as a first line chemotherapy for clear cell carcinoma of the ovary

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Irinotecan (Primary) ; Carboplatin; Paclitaxel
  • Indications Carcinoma; Ovarian cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CCC-1; GCIG; JGOG 3017
  • Most Recent Events

    • 07 Jan 2014 Planned number of patients changed from 662 to 652 as reported in ISRCTN: Current Controlled Trials & European Clinical Trials Database records.
    • 27 Jun 2012 Additional lead trial centre identified as reported by EudraCT.
    • 27 Jul 2011 Actual end date (31 Dec 2010) added as reported by as reported by ISRCTN: Current Controlled Trials.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top